Table 3 Descriptive data on the Ab measurement results for each study group
n | Mean ± Sd | Min–Max (Median) | ||
|---|---|---|---|---|
Anti-Spike IgG | IS-CoronaVac | 58 | 401.01 ± 475.49 | 1.5–2121.5 (234.25) |
IS-BNT162b2 | 46 | 8733.18 ± 10,170.45 | 0.9–40,000 (5311.2) | |
HC-CoronaVac | 142 | 1065.54 ± 2722.98 | 3.6–27,652.4 (457.85) | |
HC-BNT162b2 | 121 | 12,567.91 ± 11,109.85 | 126.2–40,000 (8842.8) | |
INF | 74 | 3674.51 ± 5722.6 | 0.5–28,717.9 (1283.15) | |
Anti-Spike IgA | IS-CoronaVac | 35 | 0.18 ± 0.46 | 0–2.55 (0.04) |
IS-BNT162b2 | 32 | 0.31 ± 0.51 | 0–2.04 (0.1) | |
HC-CoronaVac | 16 | 0.16 ± 0.21 | 0–0.72 (0.07) | |
HC-BNT162b2 | 53 | 0.36 ± 0.52 | 0–2.21 (0.17) | |
INF | 17 | 0.38 ± 0.35 | 0.04–1.36 (0.25) | |
Neutralizing Ab | IS-CoronaVac | 37 | 45.05 ± 22.03 | 5–87 (52) |
IS-BNT162b2 | 35 | 65.43 ± 28.08 | 5–100 (73) | |
HC-CoronaVac | 18 | 38.33 ± 27.95 | 0–76 (37.5) | |
HC-BNT162b2 | 59 | 81.53 ± 18.78 | 0–97 (90) | |
INF | 17 | 71.88 ± 15.74 | 26–94 (72) |